Identification of the 5,5-dioxo-7,8-dihydro-6H-thiopyrano[3,2-d]pyrimidine derivatives as highly selective PDE4B inhibitors

https://doi.org/10.1016/j.bmcl.2013.12.076Get rights and content

Abstract

A PDE4B subtype selective inhibitor is expected to have a wider therapeutic window than non-selective PDE4 inhibitors. In this Letter, two series of 7,8-dihydro-6H-thiopyrano[3,2-d]pyrimidine derivatives and 5,5-dioxo-7,8-dihydro-6H-thiopyrano[3,2-d]pyrimidine derivatives were evaluated for their PDE4B subtype selectivity using human PDE4B2 and PDE4D2 full length enzymes. To improve their PDE4B selectivity over PDE4D, we optimized the substituents on the pyrimidine ring and the side chain phenyl ring, resulting in several derivatives with more than 100-fold selectivity for PDE4B. Consequently, we identified 2-(3-chloro-4-methoxy-phenyl)-5,5-dioxo-7,8-dihydro-6H-thiopyrano[3,2-d]pyrimidine derivative 54 as a highly selective PDE4B inhibitor, which had potent hPDE4B inhibitory activity with an IC50 value of 3.0 nM and 433-fold PDE4B selectivity over PDE4D.

References (11)

  • A. Robichaud et al.

    J. Clin. Invest.

    (2002)
    S.E. Lehnart et al.

    Cell

    (2005)
  • A.T. Bender et al.

    Pharmacol. Rev.

    (2006)
    K.Y.J. Zhang et al.

    Exp. Opin. Ther. Targets

    (2005)
    T.J. Torphy

    Am. J. Respir. Crit. Care Med.

    (1998)
  • Z. Huang et al.

    Curr. Med. Chem.

    (2006)
    M. Houslay et al.

    Drug Discovery Today

    (2005)
    M. Cazzola et al.

    Exp. Opin. Ther. Targets

    (2007)
    A. Kodimuthali et al.

    J. Med. Chem.

    (2008)
  • K.F. Rabe

    Br. J. Pharmacol.

    (2011)
    M. Cazzola et al.

    Exp. Opin. Pharm.

    (2010)
    M.A. Giembycz et al.

    Drug Des. Dev. Ther.

    (2010)
  • M.D. Houslay et al.

    Circ. Res.

    (2007)
    M.D. Houslay et al.

    Biochem. J.

    (2003)
There are more references available in the full text version of this article.

Cited by (29)

  • The long and winding road of designing phosphodiesterase inhibitors for the treatment of heart failure

    2021, European Journal of Medicinal Chemistry
    Citation Excerpt :

    The carboxylic acid moiety interacted with polar residues in the “S pocket”, and interestingly, the hydroxyl group of tyrosine residue (Tyr274) of UCR2 domain seems to interact with this group, which would contribute to the enhancement of the PDE4B inhibitory activity. It is worth noticing that in PDE4D the tyrosine residue (Tyr274) is replaced by the phenylalanine residue (Phe196), which disfavor the interaction of the pyrimidine derivative 119 with this isoform [179]. Analysis of crystallographic structures of PDE4 shows that “S pocket” is a large region, exposed to the solvent and capable of settle bulky moieties.

  • Bicyclic 6-6 Systems: Three Heteroatoms 1:2

    2021, Comprehensive Heterocyclic Chemistry IV
  • Other Drugs for Asthma and COPD

    2021, Encyclopedia of Respiratory Medicine, Second Edition
View all citing articles on Scopus
View full text